Randomized phase III study comparing vinflunine-gemcitabine and gemcitabine-carboplatin combinations in patients ineligible to cisplatin with advanced or metastatic urothelial carcinoma.
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Vinflunine (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Jasint-2
- Sponsors Pierre Fabre
- 13 Jul 2017 This trial was completed in Spain, according to European Clinical Trials Database.
- 23 Nov 2016 This trial has been discontinued in Poland.
- 09 Aug 2016 This trial was discontinued in Austria (End Date: 27 Jul 2016).